Patrick G Enright bought $250k of VERA
director at Vera Therapeutics, Inc.. 5,882 shares at an average of $42.50, traded Dec 11, 2025, filed Dec 15, 2025.
Score components
- +15RoleDirector
- +13Trade size$250k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- 0Price contextNear the top of the 52-week range
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-25-319649, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 11, 2025 | POpen-market purchase Class A Common Stock | +5,882 | $42.50 | $250k | 5,882 | Dec 15, 2025 |
Related signals
Other insiders at Vera Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 11Weak | Vera Therapeutics, Inc. | Marshall Fordyce PRESIDENT AND CEO | $685k 18,500 shares | -7% | |
| 10Weak | Vera Therapeutics, Inc. | Marshall Fordyce PRESIDENT AND CEO | $650k 18,500 shares | -7% | |
| 39Weak | Vera Therapeutics, Inc. | Robert Brenner Chief Medical Officer | $90k 2,151 shares | -4% | |
| 61Notable | Vera Therapeutics, Inc. | Marshall Fordyce PRESIDENT AND CEO | $711k 16,925 shares | -6% | |
| 49Moderate | Vera Therapeutics, Inc. | Sean Grant CHIEF FINANCIAL OFFICER | $208k 4,949 shares | -4% | |
| 45Moderate | Vera Therapeutics, Inc. | David Lee Johnson Chief Operating Officer | $108k 2,579 shares | -5% | |
| 38Weak | Vera Therapeutics, Inc. | Laurence Matthew Skelton Chief Commercial Officer | $66k 1,582 shares | -2% | |
| 39Weak | Vera Therapeutics, Inc. | William D. Turner Chief Regulatory Officer | $92k 2,187 shares | -5% | |
| 41Moderate | Vera Therapeutics, Inc. | Joseph R Young SVP, FINANCE, CHIEF ACCT OFFCR | $131k 3,117 shares | -5% | |
| 8Weak | Vera Therapeutics, Inc. | William D. Turner Chief Regulatory Officer | $501k 10,000 shares | -31% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.